FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:07:108 | Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study Enrico Marchetta1, Andrew Östör2|8, Eugen Feist3, Prodromos Sidiropoulos4, Jérôme Avouac5, Martin Rebella6|7, Rajaie Namas9, Erin Mcdearmon Blondell10, Ivan Lagunes10, Tianming Gao10, Tim Shaw10, Suzan Attar11 | 1AbbVie Srl Roma, Italy; 2Monash University and Emeritus Research, Melbourne, Victoria, Melbourne, Australia; 3Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Vogelsang Gommern, Germany; 4Faculty of Medicine, University of Crete, Heraklion, Heraklion, Greece; 5Service de Rhumatologie, Hôpital Cochin, AP HP Centre Université Paris Cité, Parigi, France; 6Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Montevideo, Uruguay; 7Unidad de Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Montevideo, Uruguay; 8Australian National University, Camberra, Australia; 9Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, United Arab Emirates; 10AbbVie Inc., North Chicago, Illinois, United States of America Chicago, USA; 11King Abdulaziz University, Jeddah, Saudi Arabia
89 -
PO:16:227 | Anifrolumab for Systemic Lupus Erythematosus: Preliminary Safety and Efficacy Findings from the Italian Experience Paola Bizioli1|2, Chiara Orlandi1|2, Claudia Barison1|2, Cesare Tomasi3, Alessia Caproli1, Silvia Piantoni1|2, Simona Signorini4, Emirena Garrafa4, Cecilia Nalli1, Micol Frassi1, Ilaria Cavazzana1|2, Micaela Fredi1|2, Franco Franceschini1|2 | 1Rheumatology and Clinical Immunology Unit - ERN ReCONNET, ASST Spedali Civili of Brescia, Italy; 2Department of Clinical and Experimental Sciences, University of Brescia, Italy; 3Department of Clinical and Experimental Sciences, University of Brescia, Italy; 4Laboratory of Clinical Chemistry, Department of Molecular and Translational Medicine, University of Brescia, Italy
152 -
PO:36:246 | Early real-world outcomes with benralizumab in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective Richard Borrelli1, Stefania Nicola1, Federica Corradi1, Iuliana Badiu1, Marzia Boem1, Valentina Marmora1, Simone Negrini1, Luisa Brussino1. | 1SCDU Immunologia e Allergologia, AO Mauriziano, Dipartimento di Scienze Mediche, Università degli Studi di Torino, Torino, Italy.
264 -
PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse1, Marta Mosca2, David A Isenberg3, Joan T Merrill4, Thomas Dörner5, Michelle Petri6, Edward M Vital7|8, Eric F Morand9, Teri Jimenez10, Stephen Brookes11, Janine Gaiha-Rohrbach12, Christophe Martin13, Annette Nelde14, Christian Stach15 | 1Duke University - Division of Rheumatology and Immunology Durham, USA; 2University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; 3University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; 4Oklahoma Medical Research Foundation Oklahoma City, USA; 5Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; 6Johns Hopkins University School of Medicine Baltimore, USA; 7University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; 8Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; 9Monash University - Centre for Inflammatory Diseases Melbourne, Australia; 10UCB Raleigh, USA; 11Biogen Maidenhead, United Kingdom; 12Biogen Cambridge, USA; 13UCB Slough, United Kingdom; 14Biogen Baar, Switzerland; 15UCB Monheim am Rhein, Germany
146 -
S02:5 | Combined anti-IL-5/IL-5r and dupilumab therapy in eosinophilic granulomatosis with polyangiitis: a European retrospective study Miriam Guerini1, Pavel Novikov2, Roberto Padoan3, Georgina Espigol Frigolé4, Jan Willem Cohen Tervaert5, Vincent Grobost6, Laurent Guilleminault7, Jan Walter Schroeder8, Bernhard Hellmich9, Joana Martins Martinho10, Camillo Ribi11, Matthieu Groh12, Benjamin Terrier13. | 1IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy; 2Sechenov University, Moscow, Russia; 3University of Padova, Padova, Italy; 4Hospital Clinic, University of Barcelona, Barcelona, Spain; 5University of Alberta, Edmonton, Canada; 6CHU Estaing Clermont-Ferrand France; 7Toulouse University Toulouse France; 8ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; 9Medius Kliniken Kirchheim-Teck Germany; 10ULS Santa Maria, Lisbon, Portugal; 11Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 12Hopital Foch, Suresnes, France; 13Service de Medecine interne, Hopital Cochin, AP-HP, Paris, France.
315 -
PO:16:232 | Belimumab step-down dose spacing in patients with systemic lupus erythematosus in persistent clinical remission: experience from a multicentric cohort Alice Bartoletti1, Laura Giudice1, Lorenza Maria Argolini1|2, Giuseppe Alvise Ramirez3, Luca Moroni3, Tommaso Schioppo4, Chiara Bellocchi5|6, Annalaura Fasiello6, Lorenzo Beretta6, Lorenzo Dagna3, Roberto Caporali1, Maria Gerosa1. | 1UO Clinica Reumatologica, ASST Gaetano Pini CTO, Milano, Italy; 2UOC Medicina fisica e riabilitazione specialistica, ASST Gaetano Pini CTO, Milano, Italy; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffa Milano Italy; 4Medicina Generale II, Servizio di Reumatologia, Ospedale San Paolo, ASST Santi Paolo Carlo, Milano, Italy; 5Department of Clinical Sciences and Community Health, University of Milan, Dipartimeto di Eccellenza 2023-2027, Milano, Italy; 6Referral Centre for Systemic Autoimmune DIseases, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
343 -
PO:37:260 | Mepolizumab in the treatment of patients with eosinophilic granulomatosis with polyangiitis: real-life experience from a single-center cohort Eleonora Bruschi1, Fabrizio Angeli1, Alessandro Belotti Masserini1, Stefania Bertocchi1, Silvia Breda1, Elide Lupi1, Valeria Rossi1, Tania Ubiali1, Massimiliano Limonta1 | 1ASST Papa Giovanni XXIII Bergamo Italy
229 -
PO:06:086 | Updated Systematic Literature Review and meta-analysis to Inform the Italian Society of Rheumatology Recommendations on the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease Angelo Fassio1, Marco Sebastiani9|10, Francesco Pollastri1, Chiara Crotti4, Nicola Ughi5, Enrico De Lorenzis6, Silvia Mancuso7, Massimo Radin8, Francesca Cozzini9, Greta Carrara11, Gianpiero Landolfi11, Roberto Rozza11, Andreina Manfredi2|3 | 1Rheumatology Unit, University of Verona, Verona, Italy; 2University of Modena and Reggio Emilia, Reggio Emilia, Italy; 3Rheumatology Unit, AUSL-IRCCS, Reggio Emilia, Italy; 4Bone Disease Unit, Department of Rheumatology and Medical Science, ASST-G.Pini-CTO, Milan, Italy; 5Division of Rheumatology, Multispecialist Medical Department, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; 6Department of Aging Diseases, Orthopedic and Rheumatology, Rheumatology Division, P. Gemelli, Roma, Italy; 7Rheumatology Unit, Department of Clinical, Internal, Anaesthesiologic and Cardiovascular, Sciences, Sapienza, Roma, Italy; 8CMID, San Giovanni Bosco Hub Hospital ASL Città di Torino and Department of Clinical and Biological Sciences, Turin, Italy; 9Department of Medicine and Surgery, University of Parma, Parma, Italy; 10Rheumatology Unit, AUSL Piacenza, Piacenza, Italy; 11Unità Epidemiologica, SIR, Società Italiana di Reumatologia, Milano, Italy
96 -
PO:02:023 | Monocentric analysis of systemic glucocorticoids in PsA: the art of balancing prescriptive appropriateness and risk factor management Chiara Crotti1 2, Gilberto Cincinelli1, Giorgia Trignani13, Luca Ingrao13, Miriam Perino13, Roberto Caporali13 | 1Dipartimento di Reumatologia e Scienze Mediche - UOC Clinica Reumatologica, ASST Pini-CTO, Milano; 2Dipartimento di Reumatologia e Scienze Mediche - UOC Osteoporosi e Malattie Metaboliche dell Osso - ASST Pini-CTO, Milano; 3Dipartimento di Scienze Cliniche e di Comunità - Università degli Studi di Milano, Italy
240 -
PO:26:087 | Rituximab versus glucocorticoids for IgG4-related disease: a European retrospective multi-center study of 167 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Jasmin Mahajne1, Veronica Batani1, Lorenzo Dagna1, Emanuel Della-Torre1 | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale san Raffaele Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Stavanger, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich Germany
190 -
PO:02:022 | Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies Fabian Proft1, Désirée Van Der Heijde2, Sergio Schwartzman3|4|5, Joerg Ermann6, Alexander Marten7, Ute Massow7, George Stojan8, Vanessa Taieb9, Diana Voiniciuc10, Astrid Van Tubergen11, Victoria Navarro-Compán12, Simone Angioni13, Xenofon Baraliakos14 | 1Charité-Universitätsmedizin Berlin; Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 2Department of Rheumatology, Leiden University Medical Center Leiden, The Netherlands; 3Weill Cornell Medical Center New York, USA; 4New York Presbyterian Hospital New York, USA; 5Hospital for Special Surgery New York, USA; 6Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School Boston, USA; 7UCB Monheim am Rhein Germany; 8UCB Atlanta, USA; 9UCB Colombes, France; 10UCB Slough, United Kingdom; 11Department of Medicine, Division of Rheumatology, Maastricht University Medical Center Maastricht, The Netherlands; 12Department of Rheumatology, La Paz University Hospital, IdiPaz Madrid, Spain; 13UCB Milan, Italy; 14Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany
71 -
PO:05:074 | A clinical case of a patient affected by long-standing psoriatic arthritis and multiple comorbidities treated with an anti-IL-23 therapy Maria Letizia Currò1, Angelo Tropea1, Alessandra Burgio1, Francesca Cracò1, Antonio Pezzano1, Federica Rapisarda1, Antonino Palumbo1, Valeria D'Amico1, Fabiola Atzeni1 | 1Clinica Reumatologica di Udine, Dipartimento di Medicina, ASUFC, Udine, Italy
206 -
PO:18:268 | Voclosporin as a Steroid-Sparing Agent in Lupus Nephritis Complicated by Central Serous Chorioretinopathy: A Case Report Irene Genovali1|2, Sebastiano Lorusso2, Damiano Currado1|2, Letizia Pia Di Corcia1, Ludovica Lamberti1, Annalisa Marino2, Antonio Orlando1, Maria Quadrini1, Marta Vadacca2, Marta Vomero1, Luca Navarini1|2, Roberto Giacomelli1|2 | 1Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine Rome, Italy; 2Clinical and Research Section of Rheumatology and Clinical Immunology Fondazione Policlinico Campus Biomedico Rome, Italy
177 -
PO:29:138 | Cetylated fatty acids and fibromyalgia: efficacy and tolerability in a prospective study Anna Capogna1, Marco Bardelli1, Luca Cantarini1, Bruno Frediani1 | 1UOC Reumatologia, Dipartimento di Scienze mediche, chirurgiche e neuroscienze, Università degli Studi di Siena, Italy
244 -
PO:03:033 | Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials Irene E Van Der Horst-Bruinsma1, Matthew A Brown2, Floris A Van Gaalen3, Nigil Haroon4, Lianne S Gensler5, Alexander Marten6, Myriam Manente7, George Stojan8, Thomas Vaux9, Katy White9, Atul Deodhar10, Nicola Boffini11, Martin Rudwaleit12 | 1Department of Rheumatology, Radboud University Medical Centre Nijmegen, The Netherlands; 2Genomics England London, United Kingdom; 3Department of Rheumatology, Leiden University Medical Center Leiden, The Netherlands; 4Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto Toronto, Canada; 5Department of Medicine/Rheumatology, University of California San Francisco, USA; 6UCB Monheim am Rhein Germany; 7UCB Braine-lAlleud, Belgium; 8UCB Atlanta, USA; 9UCB Slough, United Kingdom; 10Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University Portland, USA; 11IRCCS Ospedale San Raffaele Milan, Italy; 12Klinikum Bielefeld, University of Bielefeld, Bielefeld, Germany
65 -
PO:01:006 | Increased risk of cancer recurrence or mortality associated with DMARDs? Laura Scagnellato1, Giacomo Cozzi1, Mariagrazia Lorenzin1, Mariangela Salvato1, Alessandro Giollo1, Bernd Raffeiner1, Antonia Calligaro1, Teresa Del Ross1, Sara Bindoli1, Margherita Zen1, Paolo Sfriso1, Andrea Doria1, Roberta Ramonda1. | 1UOC Reumatologia, Dipartimento di Medicina dei Sistemi DIMED, Ospedale Università di Padova, Padova, Italy.
240 -
Treatment of Wegener’s granulomatosis
1541Downloads: 5374 -
PO:02:018 | After-SECs: clinical predictors of secukinumab retention in psoriatic arthritis patients with inadequate response to anti-tumor necrosis factor therapy Francesco Cristiano1, Davide Gaspare Patti1, Valentina Boni1, Stefano Di Murro1, Cesare Gavotti1, Roberta Masnata1, Giulia Calabrese2, Gerlando Natalello2, Giusy Peluso2, Augusta Ortolan1|2, Enrico De Lorenzis1|2, Maria Antonietta D'Agostino1|2. | 1Università Cattolica del Sacro Cuore, Roma, Italy; 2Divisione di Reumatologia ed Immunologia clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
244 -
PO:35:223 | Biologic therapy for sustained remission in eosinophilic myocarditis: real-world evidence from a tertiary center experience Federica Davanzo1, Caterina Menghi2, Andrea Silvio Giordani2, Anna Baritussio2, Federico Scognamiglio2, Cristina Vicenzetto2, Luca Iorio1, Renzo Marcolongo2, Cristina Basso3, Andrea Doria1, Roberto Padoan1, Alida Linda Patr Caforio2 | 1Rheumatology Unit, Department of Medicine, University of Padua Padova, Italy; 2Cardiology Unit, Department of Cardiac, Vascular, Thoracic Sciences and Public Health, University of Padua Padova, Italy; 3Cardiovascular Pathology, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua Padova, Italy
92 -
PO:17:248 | Prevention of human papillomavirus infection in women with systemic lupus erythematosus: a single-center cross-sectional study Clizia Gagliardi1, Maria Chiara Gerardi1, Bianca Lucia Palermo1, Giulia Carrea1, Maria Di Cicco1, Elena Manna1, Giulia Segatto1, Antonella Adinolfi1, Laura Belloli1, Cinzia Casu1, Silvia Cavalli1, Davide Antonio Filippini1, Matteo Longhi1, Gabriella Maioli1, Martina Schettino1, Nicola Ughi1, Elisa Verduci1, Arianna Bertolucci1, Lara Buffa1, Giulia Buonsante1, Claudia Cordini1, Eleonora Giacobbe1, Francesco Molica Colella1, Oscar Epis1 | 1ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
255 -
PO:01:011 | Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies Lianne S Gensler1, Helena Marzo-Ortega2, Vanessa Taieb3, Diana Voiniciuc4, Alexander Marten5, George Stojan6, Mindy Kim6, Paolo Marsico7, Martin Rudwaleit8 | 1Department of Medicine/Rheumatology, University of California San Francisco, USA; 2NIHR Leeds Biomedical Research Centre, University of Leeds Leeds, United Kingdom; 3UCB Colombes, France; 4UCB Slough, United Kingdom; 5UCB Monheim am Rhein Germany; 6UCB Atlanta, USA; 7UCB Milan, Italy; 8University of Bielefeld, Klinikum Bielefeld Bielefeld Germany
75 -
PO:17:259 | Anifrolumab: a new management of SLE Giorgia Montozzi1, Chiara Cocco1, Ramona Santangeli1, Lucia Gamba1, Paola Fioretti1, Letizia Curina1, Chiara Guidoni1, Edoardo Cipolletta3, Gianluca Moroncini2 | 1Scuola di Specializzazione in Medicina Interna, Università Politecnica delle Marche Ancona, Italy; 2Department of Clinical and Molecular Sciences, Università Politecnica delle Marche Ancona, Italy; 3Rheumatology Unit, Department of Clinical and Molecular Sciences , Università Politecnica delle Marche Ancona, Italy
178 -
PO:06:078 | Is difficult-to-treat rheumatoid arthritis less severe in patients with autoantibody-negative disease? retrospective analysis from a monocentric cohort. Bernardo D'Onofrio1, Maria Chiara Ditto1, Francesco Ghellere1, Giacomo Tanti1, Salvatore Panaro1, Enrico Fusaro1, Simone Parisi1. | 1AOU Città della Salute e della Scienza, Torino, Italy.
200 -
PO:35:234 | Sustained Vasculitis Quiescence and CS Reduction with Mepolizumab 100 mg Francesca Mascia1, Angelo Fassio2, Marco Zurlo1, Davide Chesini3, Francesco Pollastri2, Giovanni Adami2, Davide Gatti4, Maurizio Rossini4, Matteo Maule5, Gianentrico Senna1, Marco Caminati1 | 1University of Verona - Allergology and Clinical Immunology Verona, Italy; 2Policlinico G. B. Rossi - Rheumatology Verona, Italy; 3University of Verona - Faculty of Medicine and Surgery Verona, Italy; 4University of Verona - Rheumatology Verona, Italy; 5Policlinico G. B. Rossi - Allergology and Clinical Immunology Verona, Italy
64 -
PO:16:236 | Achieving a low disease activity state with a corticosteroid dose of 5 mg or less: observational study with anifrolumab in patients with systemic lupus erythematosus in Italy Alessandra Bortoluzzi1, Fulvia Ceccarelli2, Fabio Leo3, Paola Roccatagliata3, Chiara Tani4, Margherita Zen5 | 1Azienda Ospedaliera Universitaria Sant' Anna di Cona, Università di Ferrara Italy; 2Unità di Reumatologia, Università Sapienza Roma Italy; 3AstraZeneca S.p.a. Milano Italy; 4Università di Pisa e Azienda Ospedaliero Universitaria Pisana, Pisa Italy; 5Dipartimento di Medicina DIMED , Divisione di Reumatologia, Università di Padova, Italy
192 -
Safety of rituximab in rheumatoid arthritis
1964Downloads: 1148
